ZBTB7B

ZBTB7B (ThPOK/c-Krox) is a BTB/POZ-zinc finger transcription factor that binds GC-rich DNA sequences to activate or repress diverse target genes, functioning as a lineage-specifying regulator in T cell and NKT cell development, a metabolic transcriptional switch in adipose tissue and liver, and a context-dependent tumor suppressor or oncogenic cofactor. Its zinc finger domains mediate direct DNA contact at promoters of collagen genes, LDHA, ADPGK, GPR17, and c-Jun, while the BTB/POZ domain enables homodimerization and heterodimerization and is essential for antagonizing Runx-mediated CD4 silencing during CD4+ T cell commitment and for controlling NKT cell effector subset balance (PMID:8702912, PMID:17878336, PMID:23105140, PMID:31792077). Beyond classical transcription, ZBTB7B recruits the lncRNA–ribonucleoprotein complex Blnc1/hnRNPU to drive thermogenic gene expression in brown and beige fat, recruits the m6A demethylase ALKBH5 to regulate IL6 mRNA nuclear export, and stabilizes the androgen receptor by binding its N-terminal domain to prevent ubiquitination (PMID:28784777, PMID:32828308, PMID:41378003). ZBTB7B protein levels are themselves regulated by NEDD4-mediated ubiquitination at K450 leading to proteasomal degradation and by SUMOylation-dependent stabilization (PMID:41807371, PMID:39107297).

1. 1996 High

   Establishing ZBTB7B as a sequence-specific transcription factor: the zinc finger and C-terminal domains were mapped as the transactivation region, and the protein was shown to bind multiple GC-rich elements in collagen gene promoters, defining its basic molecular architecture.

   Evidence EMSA, reporter assays, and deletion mutagenesis on mouse collagen promoters

   PMID:8702912

   Open questions at the time

   • Crystal structure of DNA–zinc finger complex not resolved
   • In vivo relevance of collagen regulation not tested
2. 2001 Medium

   The BTB/POZ domain was identified as a dimerization interface enabling homo- and heterodimerization, and ZBTB7B was shown to also function as a transcriptional repressor of extracellular matrix genes, expanding its role beyond activation.

   Evidence Co-immunoprecipitation, EMSA, and reporter assays in stable cell lines

   PMID:11691585

   Open questions at the time

   • Identity of heterodimerization partners and their functional significance unclear
   • Repression mechanism (corepressor recruitment) not defined
3. 2007 High

   ZBTB7B was placed at the center of CD4+ T cell lineage commitment by demonstrating that it antagonizes Runx-mediated CD4 silencer activity; this required specific ZBTB7B domains and was sensitive to HDAC inhibition, indicating an epigenetic mechanism.

   Evidence Reporter assays, in vivo genetic rescue in T cell development, HDAC inhibitor treatment

   PMID:17878336

   Open questions at the time

   • Identity of the corepressor(s) whose expression ZBTB7B reduces was not determined
   • Direct chromatin occupancy at the CD4 silencer not shown by ChIP
4. 2011 High

   A ternary complex mechanism was established in which ZBTB7B physically bridges Sp1/Sp3 and NF-κB p65 on the COL1A1 promoter, explaining how NF-κB represses collagen transcription without direct DNA binding at this locus.

   Evidence Co-IP, sequential ChIP (re-ChIP), siRNA knockdown, reporter assays in scleroderma fibroblasts

   PMID:22139845

   Open questions at the time

   • Structural basis of the ternary complex not resolved
   • Whether this bridging mechanism operates genome-wide or is promoter-specific
5. 2012 High

   ZBTB7B was shown to genetically determine NKT cell effector subset identity: a BTB-domain missense mutation shifted NKT cells from CD4+IFN-γ+ to CD8+IL-17+ RORγt+ fate, revealing a lineage-specifying function beyond conventional T cells.

   Evidence ENU-derived mouse mutant (helpless), flow cytometry, cytokine profiling

   PMID:23105140

   Open questions at the time

   • Direct transcriptional targets controlling NKT subset fate not identified
   • Whether the BTB domain mutation disrupts dimerization or corepressor interaction unresolved
6. 2017 High

   ZBTB7B was discovered to function as a metabolic regulator by recruiting the Blnc1/hnRNPU lncRNA–ribonucleoprotein complex to thermogenic gene promoters, demonstrating a non-classical transcriptional activation mechanism involving lncRNA scaffolding.

   Evidence Genome-wide functional screen, proteomics, Zbtb7b knockout mice with cold challenge

   PMID:28784777

   Open questions at the time

   • Whether ZBTB7B directly binds Blnc1 RNA or contacts it through hnRNPU not resolved
   • Genome-wide map of Blnc1-dependent vs. -independent ZBTB7B target genes not provided
7. 2020 Medium

   Two studies expanded the mechanistic repertoire: an R367Q zinc finger mutation confirmed the structural basis for DNA contact in the major groove and enabled ChIP-seq mapping of ThPOK-bound loci in T cell development, while a separate study revealed a post-transcriptional role in which ZBTB7B recruits the m6A demethylase ALKBH5 to IL6 mRNA, inhibiting its nuclear export after irradiation.

   Evidence ENU mutagenesis with structural modeling and ChIP-seq (PMID:31792077); siRNA knockdown, m6A assay, co-IP of ZBTB7B–ALKBH5 (PMID:32828308)

   PMID:31792077 PMID:32828308

   Open questions at the time

   • Crystal structure of zinc finger–DNA complex still lacking
   • Whether ALKBH5 recruitment depends on ZBTB7B's BTB or zinc finger domain not tested
   • Single-lab validation of the RNA regulatory mechanism
8. 2024 High

   Multi-omic studies established ZBTB7B as a hepatic tumor suppressor that directly represses c-Jun and competes for its chromatin targets; separately, ZBTB7B was shown to transcriptionally activate LDHA with SUMOylation stabilizing ZBTB7B protein, revealing a post-translational regulatory axis.

   Evidence Hepatocyte-specific KO, ChIP-seq, transcriptomics, phosphoproteomics, genetic rescue (PMID:38225233); ChIP-qPCR, reporter assay, SUMOylation assay (PMID:39107297)

   PMID:38225233 PMID:39107297

   Open questions at the time

   • SUMOylation site(s) on ZBTB7B not mapped
   • How ZBTB7B competition with c-Jun at chromatin is resolved structurally unknown
   • Whether hepatic tumor suppression is c-Jun-exclusive or involves additional targets
9. 2025 Medium

   ZBTB7B's post-translational regulation was further defined: NEDD4 was identified as the E3 ligase that ubiquitinates ZBTB7B at K450 for proteasomal degradation; independently, ZBTB7B was shown to stabilize the androgen receptor by binding its NTD and preventing AR ubiquitination, and to enforce the luminal epithelial phenotype in breast cancer by suppressing EMT/WNT/TGFβ programs.

   Evidence K450 mutagenesis, co-IP, in vivo tumor models (PMID:41807371); AR domain mapping, cycloheximide chase, ubiquitination assay (PMID:41378003); super-enhancer profiling and gain/loss-of-function in breast cancer lines (PMID:41231242)

   PMID:41231242 PMID:41378003 PMID:41807371

   Open questions at the time

   • NEDD4–ZBTB7B interaction surface not structurally defined
   • AR stabilization mechanism in vivo not validated
   • Whether luminal phenotype enforcement is direct transcriptional repression or indirect

• Key unresolved questions include the structural basis of ZBTB7B's zinc finger–DNA interaction, the identity of corepressors through which it antagonizes Runx, the interplay between SUMOylation and NEDD4-mediated ubiquitination in controlling ZBTB7B stability, and how its RNA-regulatory function via ALKBH5 relates to its canonical transcriptional activities.
• No crystal or cryo-EM structure available
• Corepressor identity downstream of Runx antagonism unknown
• Cross-talk between SUMOylation and K450 ubiquitination unexplored
• Genome-wide scope of m6A-regulatory function undefined